Læknablaðið - ágú. 2019, Blaðsíða 29

Barst til blaðsins 20. febrúar, samþykkt til birtingar15. apríl 2019.
1. Zanger UM, Schwab M. Cytochrome P450 enzymes in
drug metabolism: Regulation of gene expression, enzyme
activities, and impact of genetic variation. Pharmacol Ther
2013; 138: 103-41.
2. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of
polypharmacy in elderly. Expert opinion on drug safety
2014; 13: 57-65.
3. Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors.
Annu Rev Biochem 2004; 73: 953-90.
4. Kelly E. Efficacy and ligand bias at the mu-opioid recept-
or. Br J Pharmacol 2013; 169: 1430-46.
5. Boyer EW. Management of Opioid Analgesic Overdose.
The New England journal of medicine 2012; 367: 146-55.
6. Lalley PM. Opioidergic and dopaminergic modulation of
respiration. Respir Physiol Neurobiol 2008; 164: 160-7.
7. Murray RB, Adler MW, Korczyn AD. The pupillary effects
of opioids. Life Sci 1983; 33: 495-509.
8. Li Y, van den Pol AN. Mu-opioid receptor-mediated
depression of the hypothalamic hypocretin/orexin arousal
system. J Neurosci 2008; 28: 2814-9.
9. Hagelberg NM, Nieminen TH, Saari TI, Neuvonen M,
Neuvonen PJ, Laine K, et al. Voriconazole drastically incr-
eases exposure to oral oxycodone. Eur J Clin Pharmacol
2009; 65: 263-71.
10. Watanabe M, Homma M, Momo K, Okoshi Y, Wada T,
Hara A, et al. Effects of voriconazole co-administration
on oxycodone-induced adverse events: a case in the retro-
spective survey. Eur J Clin Pharmacol 2011; 67: 859-61.
11. Alghothani L, Gustin J. Oxycodone-induced neurotoxicity
secondary to concurrent voriconazole use in a patient with
cancer. Journal of opioid management 2017; 13: 141-2.
12. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY,
Shen DD. Pharmacokinetics and pharmacodynamics
of oral oxycodone in healthy human subjects: role of
circulating active metabolites. Clin Pharmacol Ther 2006;
79: 461-79.
13. Smith HS. Opioid metabolism. Mayo Clin Proc 2009; 84:
613-24.
Heimildir
Arnar Bragi Ingason1
Magnús Karl Magnússon1
Gunnar Bjarni Ragnarsson2
67-year-old female who was taking oxycodone due to chronic
chest pain suffered from opioid overdose after starting treatment
with voriconazole. Voriconazole is an antifungal that inhibits
CYP3A4 activity in the liver. In the case reported herein, this led to
higher plasma concentration of oxycodone which caused severe
opioid overdose.
Opioid overdose following voriconazole treatment – case report
ENGLISH SUMMARY
1Faculty of Medicine, University of Iceland, 2 Department of Medical Oncology, Landspitali University Hospital
Keywords: Drug interactions, oxycodone, voriconazole, adverse effects, opioid, cytochrome P450.
Correspondence: Magnús Karl Magnússon, magnuskm@hi.is
S J Ú K R A T I L F E L L I
LÆKNAblaðið 2019/105 337